Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-T100 Gel for External Genital Warts
NCT01796821Phase 2Completed
- Sponsor
- G&E Herbal Biotechnology
- Start
- Aug 2014
- Primary completion
- Sep 2018
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SR-T100 in condylomata acuminata (3 arms), sponsored by G&E Herbal Biotechnology. Primary endpoint: Total clearance rate of baseline lesion(s) at 16 weeks. Started Aug 2014; status: completed.
02
Drugs
SR-T100
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT01796821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796821.